#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Internal Medicine / 2019 - 1

Systemic inflammatory response with high CRP values as the dominant symptom of multiple myeloma

Czech version

Authors: Zdeněk Král 1;  Zdeněk Adam 1;  František Folber 1;  Mojmír Moulis 2;  Miroslav Tomíška 1;  Lucie Říhová 6;  Martin Štork 1;  Alena Buliková 1,6;  Luděk Pour 1;  Marta Krejčí 1;  Viera Sandecká 1;  Renata Koukalová 3;  Zdeněk Řehák 3;  Zdeňka Čermáková 4,5
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice 1;  Patologický ústav LF MU a FN Brno, pracoviště Bohunice 2;  Oddělení nukleární medicíny, centrum PET, RECAMO, MOÚ, Brno 3;  Oddělení klinické biochemie FN Brno, pracoviště Bohunice 4;  Katedra laboratorních metod LF MU, Brno 5;  Oddělení klinické hematologie FN Brno, pracoviště Bohunice 6
Published in: Vnitř Lék 2019; 65(1): 37-44
Category: Case reports

Overview

A man aged 60 years was examined for intense inflammatory response, night sweats, subfebrile and later febrile temperatures and a weight loss of 18 kg in 7 months. CRP was 270 mg / l, i.e. more than 20 times the upper limit of the physiological range. Reactive leukocytosis (10 × 109/l), thrombocytosis (530 × 109/l), increased fibrinogen (greater than 7 g/l), and anemia with hemoglobin of 80 g/l were present. No infection or systemic autoimmune disease has been proven. The patient had normal renal function and had no osteolytic deposits detectable by FDG-PET/CT. The procalcitonin level was not elevated. The bone marrow examination revealed a 30–40% infiltration of proplasmacyte type with admixture of plasmablasts, expressing light chains λ. Monoclonal immunoglobulin IgA λ was at a low concentration of about 8 g/l and the ratio of free light chains κ/λ was 0.13. The extent of bone marrow infiltration and anemia met the criteria for the diagnosis of symptomatic multiple myeloma. Following initiation of the combination therapy using thalidomide, bortezomib and dexamethasone, the maximum decrease in the concentrations of monoclonal immunoglobulin, free light chains and CRP was observed already after the first 2 cycles of treatment. Later, during the following two 2 cycles, the disease began to progress again. The patient underwent successful stem cell collection after the application of cyclophosphamide 2.5 g/m 2 and leukocyte growth factor (G-CSF), and high-dose chemotherapy (melphalan 200 mg/m 2) with the support of stem cell transplantation. At 2 months following high-dose chemotherapy, CRP levels of the physiological range decreased, the blood count was normalized, and monoclonal immunoglobulin was not detectable. Conclusion: The chronic inflammatory response may be due to plasmocytary bone marrow infiltration even if there are no other symptoms of multiple myel­oma present, except for anemia which, however, also involves the inflammatory reaction. In this case, the systemic inflammatory reaction with high CRP levels signalled aggressive behaviour of the disease.

Key words:

CRP – multiple myeloma – procalcitonin – systemic inflammatory response

Sources
  1. Murakami H, Takada S, Hatsumi N et al. Multiple myeloma presenting high fever and high serum levels of lactic dehydrogenase, CRP, and interleukin-6. Am J Hematol 2000; 64(1): 76–77.
  2. Wiedermann D, Widermann B, Cídl K et al. Individual serum proteins and acute phase reactants in monoclonal immunoglobulinopathies (a study in patients with IgG myeloma). Neoplasma 1978; 25(2): 189–196.
  3. Klein B, Zhang XG, Jourdan M et al. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw 1990; 1(4): 193–201.
  4. Papadaki H, Kyriakou D, Foudoulakis A et al. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity. Acta Haematol 1997; 97(4): 191–195.
  5. Dubost JJ, Ristori JM, Soubrier M et al. Acute phase proteins in monoclonal gammapathies. Pathol Biol (Paris) 1991; 39(8): 769–773.
  6. Bataille R, Boccadoro M, Klein B et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80(3): 733–737.
  7. Merlini G, Perfetti V, Gobbi PG et al. Acute phase proteins and prognosis in multiple myeloma. Br J Haematol 1993; 83(4): 595–601.
  8. Tienhaara A, Pulkki K, Mattila K et al. Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. Br J Haematol 1994; 86(2): 391–393.
  9. Pelliniemi TT, Irjala K, Mattila K et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995; 85(3): 765–771.
  10. Ščudla V, Bačovský J, Budíková M et al. Sérum interleukin-6 u mnočetného myelomu. Vztah k vybraným laboratorním indikátorům nemoci. Vnitř Lék 1995; 41(9): 593–598.
  11. Špička I, Cieslar P, Procházka B et al. Prognostické faktory a markery aktivity u mnohočetného myelomu. (Výsledky Kooperativní skupiny pro diagnostiku a léčbu mnohočetného myelomu). [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)]. Čas Lék Česk 2000; 139(7): 208–212.
  12. Alexandrakis MG, Passam FH, Ganotakis ES et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol 2003; 25(1): 41–46.
  13. Kuku I, Bayraktar MR, Kaya E et al. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma. Mediators Inflamm 2005; 3: 171–174. Dostupné z DOI: <http://dx.doi.org/10.1155/MI.2005.171>.
  14. Sezer O, Niemöller K, Eucker J et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 2000; 79(10): 574–577.
  15. Alexandrakis MG, Kyriakou DS, Passam F et al. Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate. Ann Hematol 2001; 80(6): 349–353.
  16. Kaneko M, Kanda Y, Oshima K et al. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan. Ann Hematol 2002; 81(1): 33–36.
  17. Vesole DH, Tricot G, Jagannath S et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996; 88(3): 838–847.
  18. Barlogie B, Tricot GJ, van Rhee F et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135(2): 158–164. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2141.2006.06271.x>.
  19. Fassas AB, Miceli MH, Grazzlutti M et al. E. Serial measurement of serum C-reactive protein levels can identify patients at risk for severe complications following autologous stem cell transplantation. Leuk Lymphoma 2005; 46(8): 1159–1161. Dostupné z DOI: <http://dx.doi.org/10.1080/10428190500086121>.
  20. Tomasiuk R, Gawroński K, Rzepecki P et al. The evaluation of NT-proCNP, C-reactive protein and serum amyloid A protein concentration in patients with multiple myeloma undergoing stem cell transplantation. Leuk Res 2016; 47: 123–127. Dostupné z DOI: <http://dx.doi.org/10.1016/j.leukres.2016.05.017>.
  21. Chakraborty R, Muchtar E, Kumar SK et al. Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. Bone Marrow Transplant 2018; 53(2): 155–161. Dostupné z DOI: <http://dx.doi.org/10.1038/bmt.2017.228>.
  22. Harada T, Ozaki S, Oda A et al. Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma. Int J Hematol 2013; 97(6): 743–748. Dostupné z DOI: <http://dx.doi.org/10.1007/s12185–013–1321–0>.
  23. Lust JA, Lacy MQ, Zeldenrust SR et al. Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. Am J Hematol 2016; 91(6): 571–574. Dostupné z DOI: <http://dx.doi.org/10.1002/ajh.24352>.
  24. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002; 4(3): 250–255.
  25. Legouffe E, Rodriguez C, Picot MC et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin‘s lymphoma. Leuk Lymphoma 1998; 31(3–4): 351–357. Dostupné z DOI: <http://dx.doi.org/10.3109/10428199809059228>.
  26. Samsudin I, Vasikaran SD. Clinical utility and Measurment of prokalcionin. Clin Biochem Rev 2017; 38(2): 59–68.
  27. Machálková K, Maisnar V. Využití prokalcitoninu v diferenciální diagnostice febrilií u pacientů s mnohočetným myelomem. [The role of procalcitonin in the differential diagnosis of fever in patients with multiple myeloma]. Klin Onkol 2011; 24(4): 298–301.
  28. Neyrinck MM, Vrielink H Calculations in apheresis. J Clin Apher 2015; 30(1): 38–42. Dostupné z DOI: <http://dx.doi.org/10.1002/jca.21347>.
Labels
Diabetology Endocrinology Internal medicine Clinical microbiology Paediatrics General practitioner for children and adolescents General practitioner for adults
Prescription and dosage of RAAS inhibitors in patients with chronic heart failure in the FAR NHL registry
Non-celiac gluten/wheat sensitivity: still more questions than answers
Diagnostic pitfalls of celiac disease
Potential possibility of phosphocreatine usage in internal medicine
Direct oral anticoagulants in oncology in clinical praxis
The combination of acromegaly and Klinefelter syndrome in one patient
Article was published in

Internal Medicine

Issue 1
2019 Issue 1
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#